---
title: "禮來的下一代減肥藥在試驗中取得了接近減肥手術的效果"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/287231633.md"
description: "禮來的下一代肥胖藥物 retatrutide 在第三階段臨牀試驗中顯示出良好的結果，達到的減重效果可與減肥手術相媲美。在 TRIUMPH-1 試驗中，參與者在 80 周內以 12 毫克劑量平均減重 28.3%。儘管有一些輕微的副作用，但該藥物的療效使其在減重市場中成為強有力的競爭者。禮來股票在盤前交易中上漲了 1%，而競爭對手諾和諾德的股票則小幅下跌"
datetime: "2026-05-21T13:42:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287231633.md)
  - [en](https://longbridge.com/en/news/287231633.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287231633.md)
---

# 禮來的下一代減肥藥在試驗中取得了接近減肥手術的效果

Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, **retatrutide, which delivered weight-loss results on par with** those of bariatric surgery.

In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved **meaningful weight loss across all tested doses after 80 weeks**:

-   12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight.
-   9 mg dose: average weight loss of 64.4 pounds, or 25.9%.
-   4 mg dose: average weight loss of 47.2 pounds, or 19%

Ahead of the results, _RBC Capital Markets analyst Trung Huynh_ said the **key success range** would be 28% to 30% weight loss.

Lilly's 12 mg dose appears to have cleared the low end of Huynh's bar, with patients losing an average of 28.3% of their body weight over 80 weeks.

"**We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine**," Kenneth Custer, president of Lilly Cardiometabolic Health, told Bloomberg in an interview.

Custer added, "I think we can definitively check the box" based on the data that "retatrutide moves the goalpost on max efficacy."

Retatrutide is a **first-in-class triple hormone receptor agonist**targeting **GIP, GLP-1, and glucagon**, positioning it as potentially superior to current weight-loss drugs such as Lilly's Zepbound, Novo Nordisk's Wegovy, and copycat GLP-1s.

Lilly noted some downsides to taking the drug in the trial:

> _Events of dysesthesia and urinary tract infections were generally mild to moderate, the majority resolved during treatment, and most participants continued taking retatrutide_

In markets, Lilly shares rose about 1% in premarket trading in New York, while shares of the Wegovy competitor, Novo Nordisk, traded in Copenhagen, fell slightly.

**Latest in the GLP-1 space:**

-   HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook

The **key question** is whether bariatric surgery begins to lose favor among patients as next-generation obesity medications replicate, or come close to replicating, surgery-level weight loss without an invasive procedure.

### 相關股票

- [LLY.US](https://longbridge.com/zh-HK/quote/LLY.US.md)
- [ELIL.US](https://longbridge.com/zh-HK/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/zh-HK/quote/LLYX.US.md)
- [NVOX.US](https://longbridge.com/zh-HK/quote/NVOX.US.md)
- [RY.US](https://longbridge.com/zh-HK/quote/RY.US.md)
- [NVO.US](https://longbridge.com/zh-HK/quote/NVO.US.md)
- [HIMS.US](https://longbridge.com/zh-HK/quote/HIMS.US.md)

## 相關資訊與研究

- [減肥神藥與華盛頓的權力迴廊｜藍血工廠](https://longbridge.com/zh-HK/news/286663213.md)
- [Nature Medicine：禮來口服減肥藥可在停用 GLP-1 類注射劑後，長期維持減肥效果](https://longbridge.com/zh-HK/news/286663823.md)
- [諾和諾德的下一場減肥戰：贏下美國之外的市場](https://longbridge.com/zh-HK/news/286740414.md)
- [告別 “溜溜球效應”！禮來口服減肥藥及腸道菌羣補充劑成對抗體重反彈新答案](https://longbridge.com/zh-HK/news/286211066.md)
- [諾和諾德上調財測 押注口服減肥藥賽道反攻 禮來領先但優勢縮小](https://longbridge.com/zh-HK/news/285452404.md)